Short-read Sequencing Market by Technology, Product, Workflow, Application, End-User

List of Tables

The Short-read Sequencing Market was valued at USD 5.81 billion in 2023, expected to reach USD 6.73 billion in 2024, and is projected to grow at a CAGR of 15.98%, to USD 16.41 billion by 2030.

Short-read sequencing is a high-throughput technology used to determine the sequence of short DNA fragments, pivotal in genomics research, personalized medicine, and biotechnology. It is indispensable for genome-wide association studies, single-cell sequencing, and diagnostic testing due to its affordability, efficiency, and accuracy. Key applications include genetic disorder diagnostics, cancer genomics, and agricultural biotechnology with major end-users being research institutions, diagnostic labs, and pharmaceutical companies. The market is buoyed by technological advancements, decreasing sequencing costs, and increasing demand for personalized medicine. Integration with bioinformatics and AI for data analysis enhances its utility. However, limitations include short reads' inability to span repetitive regions and complex genome assemblies, leading to challenges in accuracy and interpretation without the support of long-read technologies. The market growth is also challenged by ethical issues concerning genomic data privacy and regulatory complexities. Numerous opportunities lie in enhancing sequencing accuracy through hybrid approaches combining short and long reads or improving algorithms for data interpretation. Innovation can also focus on developing portable sequencing devices, expanding cloud-based genomic data solutions, and integrating sequencing into point-of-care diagnostics for broader healthcare applications. The market is characterized by rapid innovation, competitive collaboration, and integration of multi-omics approaches. Companies should invest in R&D to refine technologies, address data privacy concerns, and advocate for continuous stakeholder engagement to navigate regulatory landscapes effectively. Strategic partnerships with AI and bioinformatics firms can also provide an edge in data handling capabilities, personalized medicine innovations, and expansion into untapped markets. As the field evolves, stakeholders must focus on creating value through enhanced sequencing solutions that address both current limitations and emerging healthcare needs.

KEY MARKET STATISTICS
Base Year [2023]	USD 5.81 billion
Estimated Year [2024]	USD 6.73 billion
Forecast Year [2030]	USD 16.41 billion
CAGR (%)	15.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Short-read Sequencing Market

The Short-read Sequencing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising demand for personalized medicine and companion diagnostics
- Increasing demand attributed to low-cost sequencing in detection of unknown genetic variants in clinical research
- Surge in demand from application areas such as oncology, infectious disease, reproductive screening and pharmacogenomics
Market Restraints
- Shortage of skilled professionals and high cost
Market Opportunities
- Ongoing developments to decrease the cost of genome sequencing
- Growing collaboration for genetic sequencing
Market Challenges
- Dearth of required infrastructure in emerging economies

Porter's Five Forces: A Strategic Tool for Navigating the Short-read Sequencing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Short-read Sequencing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Short-read Sequencing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Short-read Sequencing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Short-read Sequencing Market

A detailed market share analysis in the Short-read Sequencing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Short-read Sequencing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Short-read Sequencing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Short-read Sequencing Market

A strategic analysis of the Short-read Sequencing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Short-read Sequencing Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., Agilent Technologies, Inc., Almac Group, Azenta Life Sciences, BGI Genomics Co., Ltd., Eurofins Genomics LLC, F. Hoffmann La Roche AG, General Electric Company, Genexa AG, GenScript Biotech Corporation, Illumina, Inc., PerkinElmer, Inc., Qiagen N.V., Seven Bridges Genomics, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Short-read Sequencing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Technology, market is studied across Next-Generation Sequencing and Sanger Sequencing.
Based on Product, market is studied across Consumables, Instruments, and Services.
Based on Workflow, market is studied across Data Analysis, Pre-Sequencing, and Sequencing.
Based on Application, market is studied across Agrigenomics & Forensics, Clinical Investigation, Consumer Genomics, HLA Typing & Immune System Monitoring, Metagenomics, Epidemiology & Drug Development, Oncology, and Reproductive Health.
Based on End-User, market is studied across Academic Research, Clinical Research, Hospitals & Clinics, and Pharma & Biotech Entities.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-AD36CD898498

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising demand for personalized medicine and companion diagnostics
  - 5.1.1.2. Increasing demand attributed to low-cost sequencing in detection of unknown genetic variants in clinical research
  - 5.1.1.3. Surge in demand from application areas such as oncology, infectious disease, reproductive screening and pharmacogenomics
- 5.1.2. Restraints
  - 5.1.2.1. Shortage of skilled professionals and high cost
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing developments to decrease the cost of genome sequencing
  - 5.1.3.2. Growing collaboration for genetic sequencing
- 5.1.4. Challenges
  - 5.1.4.1. Dearth of required infrastructure in emerging economies
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Short-read Sequencing Market, by Technology

6.1. Introduction
6.2. Next-Generation Sequencing
6.3. Sanger Sequencing

7. Short-read Sequencing Market, by Product

7.1. Introduction
7.2. Consumables
7.3. Instruments
7.4. Services

8. Short-read Sequencing Market, by Workflow

8.1. Introduction
8.2. Data Analysis
8.3. Pre-Sequencing
8.4. Sequencing

9. Short-read Sequencing Market, by Application

9.1. Introduction
9.2. Agrigenomics & Forensics
9.3. Clinical Investigation
9.4. Consumer Genomics
9.5. HLA Typing & Immune System Monitoring
9.6. Metagenomics, Epidemiology & Drug Development
9.7. Oncology
9.8. Reproductive Health

10. Short-read Sequencing Market, by End-User

10.1. Introduction
10.2. Academic Research
10.3. Clinical Research
10.4. Hospitals & Clinics
10.5. Pharma & Biotech Entities

11. Americas Short-read Sequencing Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Short-read Sequencing Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Short-read Sequencing Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation

Companies Mentioned

1. 10x Genomics, Inc.
2. Agilent Technologies, Inc.
3. Almac Group
4. Azenta Life Sciences
5. BGI Genomics Co., Ltd.
6. Eurofins Genomics LLC
7. F. Hoffmann La Roche AG
8. General Electric Company
9. Genexa AG
10. GenScript Biotech Corporation
11. Illumina, Inc.
12. PerkinElmer, Inc.
13. Qiagen N.V.
14. Seven Bridges Genomics, Inc.
15. Thermo Fisher Scientific Inc.